河北男科医院费用联盟

前列腺增生|治疗良性前列腺增生症在研新药及其临床研究进展

慧保健 2019-10-08 16:40:04


导语

良性前列腺增生症是老年男性人群中普遍存在的疾病。超过一半的50岁以上男性将可能患有良性前列腺增生症(BPH)。此外,这些患者中有一半以上将会进展为BPH继发的下尿路症状(LUTS)疾病。LUTS将影响个人储存和排空尿液的能力,并导致生活质量(QoL)下降。BPH患者的夫妻伴侣也同时会受到睡眠障碍、社交生活受阻和心理负担加重等各方面的不利影响。伴随着人口老龄化趋势的加剧,BPH及其继发的LUTS的患病率和发病率还将持续稳步增加。预计到2024年,全球BPH药物市场将达到52亿美元。患者求医治疗的最常见原因是由于疾病症状影响了他们的生活质量,希望通过药物治疗来缓解症状,防止症状恶化。这种治疗方案的主要目标是改善患者的生活质量。目前最常见的被证明可以有效治疗BPH的两类药物是α受体阻滞剂和5-α还原酶抑制剂(5ARIs)。但对部分患者来说,还是无法忍受这两类药物所带来的不良反应。因此BPH治疗领域仍存在着临床需求,对于不同作用机制新药的开发方兴未艾。但无论治疗机制如何,都将必须考虑相关风险,包括症状缓解、不良反应、短期和长期并发症和对性功能的影响等。本文汇总了目前正处于临床开发阶段的BPH/LUTS治疗药物,并通过表格形式给读者清晰展示了各个药物在临床开发阶段的研究进展。


关键词:前列腺增生;药品研发

处于临床开发阶段的BPH/LUTS治疗药物及其研究进展  

处于临床开发阶段的BPH/LUTS治疗药物及其研究进展详见表1和表2



小结


尽管目前已有许多药物治疗方案被推荐用于治疗BPH及其继发的LUTS,但这些药物伴随的不良反应较多,使得难以评价药物的有效性。此外,由于LUTS和BPH的病因尚未完全被了解,这使得治疗进一步复杂化。正在进行的临床试验已经确定了一些潜在的药物治疗靶点,因此目前我们正在期待大规模的随机试验来评估这些新的药物疗法与安慰剂和/或其他目前正被广泛使用药物之间真正的实力对比。


参考

文献

Dominique Thomas, Bilal Chughtai, Mitali Kini & AlexisTe (2017) Emerging drugs for the treatment of benign prostatic hyperplasia,Expert Opinion on Emerging Drugs, 22:3,201-212, DOI:10.1080/14728214.2017.1369953。


Abstract Benign prostatic hyperplasia (BPH) is a common condition affecting over 50% of men as they reach their 5th decade of life. This leads to a number of sequelae such as lower urinary tract symptoms, urinary retention and a decrease in quality of life. Currently, the available treatments for BPH are alpha blockers and 5-alpha reductase inhibitors. Clinical studies have demonstrated these medical options are effective in alleviating a patient's symptoms, however there are a number of side effects. There is a paucity of information regarding long-term use of these medications. The purpose of this review is to identify potential and emerging medications for the treatment of BPH. Areas covered: Articles used in this review were retrieved from Pubmed, Google and through searching the PharmaProjects database over the last 10 years, giving the reader an in-depth knowledge about the current pharmacological agents available and other potential treatments for BPH. Expert opinion: The new paradigm of BPH treatment depends on addressing a patient's specific constellation of symptoms. This allows to tailor therapy of increasing efficacy and reduce adverse events that our patients have by increasing dosage.



来源:药渡